Proteasome inhibitors, including curcumin, improve pancreatic β-cell function and insulin sensitivity in diabetic mice

Nutrition and Diabetes

Volumn 6, Issue 4, 2016, Pages

  Weisberg, S ^a   Leibel, R ^a   Tortoriello, D V ^a,b  

^a Department of Medicine   (United States)

^b Sher Institute for Reproductive Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CURCUMIN; EPOXOMICIN; GLYCOSYLATED HEMOGLOBIN; INSULIN; LEPTIN RECEPTOR; OLIGOPEPTIDE; POLYPHENOL; PROTEASOME INHIBITOR; TRIPTERINE; TRITERPENE;

3T3 CELL LINE; ANIMAL; BLOOD; BODY COMPOSITION; C57BL MOUSE; CELL SURVIVAL; CYTOLOGY; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DIETARY SUPPLEMENT; DRUG EFFECTS; GENETICS; HOMEOSTASIS; HYPERGLYCEMIA; INSULIN RESISTANCE; MALE; METABOLISM; MOUSE; OBESITY; PANCREAS ISLET BETA CELL; SECRETION (PROCESS);

3T3-L1 CELLS; ANIMALS; BODY COMPOSITION; CELL SURVIVAL; CURCUMIN; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DIETARY SUPPLEMENTS; HEMOGLOBIN A, GLYCOSYLATED; HOMEOSTASIS; HYPERGLYCEMIA; INSULIN; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; MALE; MICE; MICE, INBRED C57BL; OBESITY; OLIGOPEPTIDES; POLYPHENOLS; PROTEASOME INHIBITORS; RECEPTORS, LEPTIN; TRITERPENES;

EID: 84988464681     PISSN: None     EISSN: 20444052     Source Type: Journal    
DOI: 10.1038/NUTD.2016.13     Document Type: Article

References (83)

1. Engelgau MM, Geiss LS, Saaddine JB, Boyle JP, Benjamin SM, Gregg EW et al. The evolving diabetes burden in the United States. Ann Intern Med 2004; 140: 945–950.
2. Pi-Sunyer FX. The obesity epidemic: pathophysiology and consequences of obesity. Obes Res 2002; 10 (Suppl 2): 97S–104S.
3. Wyatt SB, Winters KP, Dubbert PM. Overweight and obesity: prevalence, consequences, and causes of a growing public health problem. Am J Med Sci 2006; 331: 166–174.
4. DeStefano F, Ford ES, Newman J, Stevenson JM, Wetterhall SF, Anda RF et al. Risk factors for coronary heart disease mortality among persons with diabetes. Ann Epidemiol 1993; 3: 27–34.
5. Cinti S, Mitchell G, Barbatelli G, Murano I, Ceresi E, Faloia E et al. Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. J Lipid Res 2005; 46: 2347–2355.
6. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003; 112: 1796–1808.
7. Matsuzawa Y. The metabolic syndrome and adipocytokines. FEBS Lett 2006; 580: 2917–2921.
8. Guzik TJ, Mangalat D, Korbut R. Adipocytokines—novel link between inflammation and vascular function? J Physiol Pharmacol 2006; 57: 505–528.
9. Eldor R, Yeffet A, Baum K, Doviner V, Amar D, Ben-Neriah Y et al. Conditional and specific NF-kappaB blockade protects pancreatic beta cells from diabetogenic agents. Proc Natl Acad Sci USA 2006; 103: 5072–5077.
10. Ahren B. Type 2 diabetes, insulin secretion and beta-cell mass. Curr Mol Med 2005; 5: 275–286.
11. Chitturi S, George J. Hepatotoxicity of commonly used drugs: nonsteroidal anti-inflammatory drugs, antihypertensives, antidiabetic agents, anticonvulsants, lipid-lowering agents, psychotropic drugs. Semin Liver Dis 2002; 22: 169–183.
12. Spiller HA, Sawyer TS. Toxicology of oral antidiabetic medications. Am J Health Syst Pharm 2006; 63: 929–938.
13. Chainani-Wu N. Safety and anti-inflammatory activity of curcumin: a component of tumeric (Curcuma longa). J Altern Complement Med 2003; 9: 161–168.
14. Lodha R, Bagga A. Traditional Indian systems of medicine. Ann Acad Med Singapore 2000; 29: 37–41.
15. Aggarwal S, Ichikawa H, Takada Y, Sandur SK, Shishodia S, Aggarwal BB. Curcumin (diferuloylmethane) down-regulates expression of cell proliferation and antiapoptotic and metastatic gene products through suppression of IkappaBal-pha kinase and Akt activation. Mol Pharmacol 2006; 69: 195–206.
16. Banerji A, Chakrabarti J, Mitra A, Chatterjee A. Effect of curcumin on gelatinase A (MMP-2) activity in B16F10 melanoma cells. Cancer Lett 2004; 211: 235–242.
17. Belakavadi M, Salimath BP. Mechanism of inhibition of ascites tumor growth in mice by curcumin is mediated by NF-kB and caspase activated DNase. Mol Cell Biochem 2005; 273: 57–67.
18. Busquets S, Carbo N, Almendro V, Quiles MT, Lopez-Soriano FJ, Argiles JM. Curcumin, a natural product present in turmeric, decreases tumor growth but does not behave as an anticachectic compound in a rat model. Cancer Lett 2001; 167: 33–38.
19. Campbell FC, Collett GP. Chemopreventive properties of curcumin. Fut Oncol 2005; 1: 405–414.
20. Chakraborty S, Ghosh U, Bhattacharyya NP, Bhattacharya RK, Roy M. Inhibition of tel-omerase activity and induction of apoptosis by curcumin in K-562 cells. Mutat Res 2006; 569: 81–90.
21. Chen A, Xu J, Johnson AC. Curcumin inhibits human colon cancer cell growth by suppressing gene expression of epidermal growth factor receptor through reducing the activity of the transcription factor Egr-1. Oncogene 2006; 25: 278–287.
22. Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, Shen TS et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 2001; 21: 2895–2900.
23. Choudhuri T, Pal S, Agwarwal ML, Das T, Sa G. Curcumin induces apoptosis in human breast cancer cells through p53-dependent Bax induction. FEBS Lett 2002; 512: 334–340.
24. Chuang SE, Kuo ML, Hsu CH, Chen CR, Lin JK, Lai GM et al. Curcumin-containing diet inhibits diethylnitrosamine-induced murine hepatocarcinogenesis. Carcino-genesis 2000; 21: 331–335.
25. Banerjee M, Tripathi LM, Srivastava VM, Puri A, Shukla R. Modulation of inflammatory mediators by ibuprofen and curcumin treatment during chronic inflammation in rat. Immunopharmacol Immunotoxicol 2003; 25: 213–224.
26. Brouet I, Ohshima H. Curcumin, an anti-tumour promoter and anti-inflammatory agent, inhibits induction of nitric oxide synthase in activated macrophages. Biochem Biophys Res Commun 1995; 206: 533–540.
27. Chan MM, Ho CT, Huang HI. Effects of three dietary phytochemicals from tea, rosemary and turmeric on inflammation-induced nitrite production. Cancer Lett 1995; 96: 23–29.
28. Cole GM, Morihara T, Lim GP, Yang F, Begum A, Frautschy SA. NSAID and antioxidant prevention of Alzheimer's disease: lessons from in vitro and animal models. Ann NY Acad Sci 2004; 1035: 68–84.
29. Giri RK, Rajagopal V, Kalra VK. Curcumin, the active constituent of turmeric, inhibits amyloid peptide-induced cytochemokine gene expression and CCR5-mediated chemotaxis of THP-1 monocytes by modulating early growth response-1 transcription factor. J Neurochem 2004; 91: 1199–1210.
30. Weisberg SP, Leibel R, Tortoriello DV. Dietary curcumin significantly improves obesity-associated inflammation and diabetes in mouse models of diabesity. Endocrinology 2008; 149: 3549–3558.
31. Brennan P, O'Neill LA. Inhibition of nuclear factor kappaB by direct modification in whole cells—mechanism of action of nordihydroguaiaritic acid, curcumin and thiol modifiers. Biochem Pharmacol 1998; 55: 965–973.
32. Chen A, Xu J. Activation of PPAR{gamma} by curcumin inhibits Moser cell growth and mediates suppression of gene expression of cyclin D1 and EGFR. Am J Physiol Gastrointest Liver Physiol 2005; 288: G447–G456.
33. Zheng S, Chen A. Activation of PPARgamma is required for curcumin to induce apoptosis and to inhibit the expression of extracellular matrix genes in hepatic stellate cells in vitro. Biochem J 2004; 384: 149–157.
34. Zhang F, Altorki NK, Mestre JR, Subbaramaiah K, Dannenberg AJ. Curcumin inhibits cyclooxygenase-2 transcription in bile acid-and phorbol ester-treated human gastrointestinal epithelial cells. Carcinogenesis 1999; 20: 445–451.
35. Goel A, Boland CR, Chauhan DP. Specific inhibition of cyclooxygenase-2 (COX-2) expression by dietary curcumin in HT-29 human colon cancer cells. Cancer Lett 2001; 172: 111–118.
36. Reddy BS, Rao CV. Novel approaches for colon cancer prevention by cyclooxygenase-2 inhibitors. J Environ Pathol Toxicol Oncol 2002; 21: 155–164.
37. Kang G, Kong PJ, Yuh YJ, Lim SY, Yim SV, Chun W et al. Curcumin suppresses lipopolysaccharide-induced cyclooxygenase-2 expression by inhibiting activator protein 1 and nuclear factor kappab bindings in BV2 microglial cells. J Pharmacol Sci 2004; 94: 325–328.
38. Wallace JM. Nutritional and botanical modulation of the inflammatory cascade— eicosanoids, cyclooxygenases, and lipoxygenases—as an adjunct in cancer ther-apy. Integr Cancer Ther 2002; 1: 7–37; discussion.
39. Chen YR, Tan TH. Inhibition of the c-Jun N-terminal kinase (JNK) signaling pathway by curcumin. Oncogene 1998; 17: 173–178.
40. Parra M, Lluis F, Miralles F, Caelles C, Munoz-Canoves P. The cJun N-terminal kinase (JNK) signaling pathway mediates induction of urokinase-type plasmino-gen activator (uPA) by the alkylating agent MNNG. Blood 2000; 96: 1415–1424.
41. Dikshit P, Goswami A, Mishra A, Chatterjee M, Jana NR. Curcumin induces stress response, neurite outgrowth and prevent NF-kappaB activation by inhibiting the proteasome function. Neurotox Res 2006; 9: 29–37.
42. Dikshit P, Goswami A, Mishra A, Nukina N, Jana NR. Curcumin enhances the polyglutamine-expanded truncated N-terminal huntingtin-induced cell death by promoting proteasomal malfunction. Biochem Biophys Res Commun 2006; 342: 1323–1328.
43. Jana NR, Dikshit P, Goswami A, Nukina N. Inhibition of proteasomal function by curcumin induces apoptosis through mitochondrial pathway. J Biol Chem 2004; 279: 11680–11685.
44. Wyke SM, Russell ST, Tisdale MJ. Induction of proteasome expression in skeletal muscle is attenuated by inhibitors of NF-kappaB activation. Br J Cancer 2004; 91: 1742–1750.
45. Singh S, Aggarwal BB. Activation of transcription factor NF-kappa B is suppressed by curcumin (diferuloylmethane) [corrected]. J Biol Chem 1995; 270: 24995–25000.
46. Kumar A, Dhawan S, Hardegen NJ, Aggarwal BB. Curcumin (diferuloylmethane) inhibition of tumor necrosis factor (TNF)-mediated adhesion of monocytes to endothelial cells by suppression of cell surface expression of adhesion mole-cules and of nuclear factor-kappaB activation. Biochem Pharmacol 1998; 55: 775–783.
47. Han SS, Chung ST, Robertson DA, Ranjan D, Bondada S. Curcumin causes the growth arrest and apoptosis of B cell lymphoma by downregulation of egr-1, c-myc, bcl-XL, NF-kappa B, and p53. Clin Immunol 1999; 93: 152–161.
48. Jobin C, Bradham CA, Russo MP, Juma B, Narula AS, Brenner DA et al. Curcumin blocks cytokine-mediated NF-kappa B activation and proinflammatory gene expression by inhibiting inhibitory factor I-kappa B kinase activity. J Immunol 1999; 163: 3474–3483.
49. Thaloor D, Miller KJ, Gephart J, Mitchell PO, Pavlath GK. Systemic administration of the NF-kappaB inhibitor curcumin stimulates muscle regeneration after traumatic injury. Am J Physiol 1999; 277: C320–C329.
50. Deeb D, Jiang H, Gao X, Hafner MS, Wong H, Divine G et al. Curcumin sensitizes prostate cancer cells to tumor necrosis factor-related apoptosis-inducing ligand/ Apo2L by inhibiting nuclear factor-kappaB through suppression of IkappaBalpha phosphorylation. Mol Cancer Ther 2004; 3: 803–812.
51. Zheng M, Ekmekcioglu S, Walch ET, Tang CH, Grimm EA. Inhibition of nuclear factor-kappaB and nitric oxide by curcumin induces G2/M cell cycle arrest and apoptosis in human melanoma cells. Melanoma Res 2004; 14: 165–171.
52. Al-Sadi RM, Kreydiyyeh SI. Mediators of interleukin-1 beta action Na(+)-K(+) ATPase in Caco-2 cells. Eur Cytokine Netw 2003; 14: 83–90.
53. Callige M, Kieffer I, Richard-Foy H. CSN5/Jab1 is involved in ligand-dependent degradation of estrogen receptor {alpha} by the proteasome. Mol Cell Biol 2005; 25: 4349–4358.
54. Chen JJ, Huang WC, Chen CC. Transcriptional regulation of cyclooxygenase-2 in response to proteasome inhibitors involves reactive oxygen species-mediated signaling pathway and recruitment of CCAAT/enhancer-binding protein delta and CREB-binding protein. Mol Biol Cell 2005; 16: 5579–5591.
55. Guo W, Shang F, Liu Q, Urim L, Zhang M, Taylor A. Ubiquitin-proteasome pathway function is required for lens cell proliferation and differentiation. Invest Ophthal-mol Vis Sci 2006; 47: 2569–2575.
56. Liacini A, Sylvester J, Li WQ, Huang W, Dehnade F, Ahmad M et al. Induction of matrix metalloproteinase-13 gene expression by TNF-alpha is mediated by MAP kinases, AP-1, and NF-kappaB transcription factors in articular chondrocytes. Exp Cell Res 2003; 288: 208–217.
57. Marinovic AC, Zheng B, Mitch WE, Price SR. Tissue-specific regulation of ubiquitin (UbC) transcription by glucocorticoids: in vivo and in vitro analyses. Am J Physiol Renal Physiol 2006; 292: F660–F666.
58. Ward C, Chilvers ER, Lawson MF, Pryde JG, Fujihara S, Farrow SN et al. NF-kappaB activation is a critical regulator of human granulocyte apoptosis in vitro. J Biol Chem 1999; 274: 4309–4318.
59. Yew EH, Cheung NS, Choy MS, Qi RZ, Lee AY, Peng ZF et al. Proteasome inhibition by lactacystin in primary neuronal cells induces both potentially neuroprotective and pro-apoptotic transcriptional responses: a microarray analysis. J Neurochem 2005; 94: 943–956.
60. Butts BD, Hudson HR, Linseman DA, Le SS, Ryan KR, Bouchard RJ et al. Proteasome inhibition elicits a biphasic effect on neuronal apoptosis via differential regulation of pro-survival and pro-apoptotic transcription factors. Mol Cell Neurosci 2005; 30: 279–289.
61. Kitiphongspattana K, Mathews CE, Leiter EH, Gaskins HR. Proteasome inhibition alters glucose-stimulated (pro)insulin secretion and turnover in pancreatic {beta}-cells. J Biol Chem 2005; 280: 15727–15734.
62. Yang W, Monroe J, Zhang Y, George D, Bremer E, Li H. Proteasome inhibition induces both pro-and anti-cell death pathways in prostate cancer cells. Cancer Lett 2006; 243: 217–227.
63. Yang H, Chen D, Cui QC, Yuan X, Dou QP. Celastrol, a triterpene extracted from the Chinese 'Thunder of God Vine,' is a potent proteasome inhibitor and suppresses human prostate cancer growth in nude mice. Cancer Res 2006; 66: 4758–4765.
64. Garrett IR, Chen D, Gutierrez G, Zhao M, Escobedo A, Rossini G et al. Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro. J Clin Invest 2003; 111: 1771–1782.
65. Chen H, Charlat O, Tartaglia LA, Woolf EA, Weng X, Ellis SJ et al. Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db/db mice. Cell 1996; 84: 491–495.
66. Bock T, Pakkenberg B, Buschard K. Increased islet volume but unchanged islet number in ob/ob mice. Diabetes 2003; 52: 1716–1722.
67. Dai Y, Desano J, Tang W, Meng X, Meng Y, Burstein E et al. Natural proteasome inhibitor celastrol suppresses androgen-independent prostate cancer progression by modulating apoptotic proteins and NF-kappaB. PLoS One 2010; 5: e14153.
68. Fricker LD, Gelman JS, Castro LM, Gozzo FC, Ferro ES. Peptidomic analysis of HEK293T cells: effect of the proteasome inhibitor epoxomicin on intracellular peptides. J Proteome Res 2012; 11: 1981–1990.
69. Abdelli S, Bonny C. JNK3 maintains expression of the insulin receptor substrate 2 (IRS2) in insulin-secreting cells: functional consequences for insulin signaling. PLoS One 2012; 7: e35997.
70. Stiles BL, Kuralwalla-Martinez C, Guo W, Gregorian C, Wang Y, Tian J et al. Selective deletion of Pten in pancreatic beta cells leads to increased islet mass and resistance to STZ-induced diabetes. Mol Cell Biol 2006; 26: 2772–2781.
71. Barbosa H, Bordin S, Stoppiglia L, Silva K, Borelli M, Del Zotto H et al. Islet neogenesis associated protein (INGAP) modulates gene expression in cultured neonatal rat islets. Regul Pept 2006; 136: 78–84.
72. Hideshima T, Chauhan D, Richardson P, Mitsiades C, Mitsiades N, Hayashi T et al. NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem 2002; 277: 16639–16647.
73. Deans KA, Sattar N. 'Anti-inflammatory' drugs and their effects on type 2 diabetes. Diabetes Technol Ther 2006; 8: 18–27.
74. Sjoholm A, Nystrom T. Inflammation and the etiology of type 2 diabetes. Diabetes Metab Res Rev 2006; 22: 4–10.
75. Hundal RS, Petersen KF, Mayerson AB, Randhawa PS, Inzucchi S, Shoelson SE et al. Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. J Clin Invest 2002; 109: 1321–1326.
76. Whitehead JP, Richards AA, Hickman IJ, Macdonald GA, Prins JB. Adiponectin—a key adipokine in the metabolic syndrome. Diabetes Obes Metab 2006; 8: 264–280.
77. Buckingham RE. Thiazolidinediones: pleiotropic drugs with potent anti-inflam-matory properties for tissue protection. Hepatol Res 2005; 33: 167–170.
78. Takebayashi K, Matsumoto S, Wakabayashi S, Inukai Y, Matsutomo R, Aso Y et al. The effect of low-dose atorvastatin on circulating monocyte chemoattractant protein-1 in patients with type 2 diabetes complicated by hyperlipidemia. Metabolism 2005; 54: 1225–1229.
79. Norlin S, Ahlgren U, Edlund H. Nuclear factor-{kappa}B activity in {beta}-cells is required for glucose-stimulated insulin secretion. Diabetes 2005; 54: 125–132.
80. Sen P, Bhattacharyya S, Wallet M, Wong CP, Poligone B, Sen M et al. NF-kappa B hyperactivation has differential effects on the APC function of nonobese diabetic mouse macrophages. J Immunol 2003; 170: 1770–1780.
81. Jaeschke A, Rincon M, Doran B, Reilly J, Neuberg D, Greiner DL et al. Disruption of the Jnk2 (Mapk9) gene reduces destructive insulitis and diabetes in a mouse model of type I diabetes. Proc Natl Acad Sci USA 2005; 102: 6931–6935.
82. Wu L, Nicholson W, Knobel SM, Steffner RJ, May JM, Piston DW et al. Oxidative stress is a mediator of glucose toxicity in insulin-secreting pancreatic islet cell lines. J Biol Chem 2004; 279: 12126–12134.
83. Gupta SC, Patchra S, Aggarwal BB, Therapeutic roles of curcumin: lessons learned from clinical trials. AAPS 2013; 15: 195–218.